Skip to main content
Premium Trial:

Request an Annual Quote

Fujirebio Europe Picks up Distribution Rights to Self-screen's RUO Anal Cancer Assay

NEW YORK — Fujirebio Europe has acquired the nonexclusive distribution rights to Self-screen's PreCursor-M AnoGyn assay in Europe, the Middle East, Africa, and Asia, the companies said on Tuesday.

The research-use-only test is designed to detect promoter hypermethylation of the genes ASCL1 and ZNF582 in anal specimens. Host cell DNA methylation is an epigenetic hallmark of human papillomavirus-induced cancers and may be useful for risk stratification of anal lesions, according to Self-screen.

Specific terms of the deal including financials were not disclosed.

The PreCursor-M AnoGyn assay "represents a significant advancement for research studies in the field of anal cancer prevention," Fujirebio Europe CEO Christiaan De Wilde said in a statement. "We wanted our customers to have access to this valuable research tool as soon as possible, ultimately catalyzing advancements in elimination of HPV-related diseases."

In late 2022, Self-screen licensed the distribution rights to its PreCursor-M+ cervical cancer assay to Ghent, Belgium-based Fujirebio.